CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 51 enrolled
Drug / intervention
Blood collection +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02955966
NCT02955966N/ACompleted
CompareCT.gov

PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis

Assistance Publique - Hôpitaux de Paris·interventional·Posted Nov 4, 2016·Updated Nov 20, 2025

In Brief

A clinical study evaluating imaging 18F-FDG-PET/CT and Blood collection for Aspergillosis and Haematological Malignancy. Completed, enrolled 51 participants across 1 site.

Detailed Summary

OPTIFIL is a pilot prospective multicenter study based over the hypothesis that the normalization of the functional imaging 18F-FDG-PET/CT during the Invasive pulmonary aspergillosis (IPA) could occur earlier than that of conventional imaging. This study evaluates the therapeutic response through a systematic 18F-FDG-PET/CT at week 6. The latter response will be correlated with the kinetics of selected biomarkers including antigens (galactomannan, β-D glucans), circulating Aspergillus DNA and anti-Aspergillus host response markers in addition to the conventional imaging tools obtained at weeks 6 and 12.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAspergillosis and Haematological Malignancy
CountriesFrance
CollaboratorsInstitut Pasteur, Paris France, URC-CIC Paris Descartes Necker Cochin

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 4, 2016
Enrollment StartJun 2, 2017
Primary CompletionMay 2, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.7 years ago

Interventions

imaging 18F-FDG-PET/CTdevice

18F-FDG PET Scan at Day 0, W6 and W12

Blood collectionbiological

Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.